Inve India ▾
ASASTRAZEN

AstraZeneca Pharma India Q1 FY25 results (Apr–Jun 2024) and concall

Healthcare · Concall AI · Call held 8 Aug 2024

Company page: AstraZeneca Pharma India share price, financials & guidance record

Source transcript

AstraZeneca India is undergoing a significant strategic transition from a manufacturing-led model to a specialist biopharmaceutical trading organization. The company delivered robust double-digit growth in FY24 and started Q1 FY25 with strong underlying momentum despite the loss of exclusivity for key brands. Management is focused on accelerating the launch of the global innovative pipeline in India to support the parent company's $80 billion revenue target by 2030.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.